האגודה למלחמה בסרטן - ביטאון לעובדי בריאות בנושא מחלת הסרטן והשלכותיה - גיליון 20 אוקטובר 2014

ביטאון לעובדי בריאות בנושא מחלת הסרטן והשלכותיה במה

רשימת ספרות

1. Goldhirsch A, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011 Aug;22(8):1736–47. 2. Sørlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001 Sep: 98(19); 10869–74. 3. Sotiriou C, Pusztai L, et al. Gene-expression signatures in breast cancer. N Engl J Med. 2009 Feb;360(8):790–800. 4. Perou C.M, et al. Molecular portraits of human breast tumours. Nature. 2000 Aug;406(6797):747–52. 5. Creighton CJ. The molecular profile of luminal B breast cancer. Biologics. 2012;6:289–97. Epub 2012 Aug 24. 6. Cui X, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005 Oct;23(30):7721–35. 7. Ignatiadis M, et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol. 2012 Jun;30(16):1996–2004. Epub 2012 Apr 16. 8. Rouzier R, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005 Aug;11(16):5678–85. 9. PaikS, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004 Dec;351(27):2817–26. Epub 2004 Dec 10. 10. van't Veer LJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002 Jan;415(6871):530–36. 11. Parker JS, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009 Mar;27(8):1160–7. Epub 2009 Feb 6. 12. Gnant M, Flipits M, Mlineritsch B, et al. Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant- recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study [abstract]. Cancer Res. 2012;72(Sup.3):P2-10-02. 13. SotiriouC, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006 Feb;98(4):262–72. 14. Ma XJ, et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res. 2008 May;14(9):2601–8. 15. Filipits M, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011 Sep;17(18):6012–20. Epub 2011 Aug 1. 16. Dubsky P, et al. EndoPredict improves the prognostic classification derived from common clinical guidelines

29. Goss PE, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003 Nov;349(19):1793–802. Epub 2003 Oct 9. 30. Jakesz R, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J. Natl Cancer Inst. 2007 Dec;99(24):1845–53. Epub 2007 Dec 11. 31. Mamounas EP,. et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol. 2008 Apr; 26(12):1965–71. Epub 2008 Mar 10. 32. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01249456, Safety and Efficacy Study of Femara (Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients; 2010 Nov [Last updated 2011 Jun]; Available from: http://clinicaltrials.gov/ct2/show/NCT01249456 33. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00754845, Letrozole in Treating Women With Primary Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy (MA17R); 2008 Sep [Last updated 2014 Feb]; Available from: http://clinicaltrials.gov/ct2/ show/NCT00754845 34. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00382070, Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer (NSABP B-42); 2006 Sep [Last updated 2013 Oct]; Available from: http:// clinicaltrials.gov/ct2/show/NCT00382070 35. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004(Apr);350(16):1655–64. 36. Coleman R, et al. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst. 2012 Jul;104(14):1059–67. 37. Gnant M, et al. S1-2: Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer [abstract]. Cancer Res. 2011;24 (Suppl. 3):S1–S2. 38. Coleman R, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann. Oncol. 2013 Feb;242):398– 405. Epub 2012 Oct 9. 39. Paterson AH, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012 Jul;13(7):734–42. Epub 2012 Jun 14. 40. Coleman RE, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011 Oct 13;365(15):1396-40.

in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013 Mar;24(3):640–7. 17. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00310180, Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial); 2006 Mar; Available from: http:// clinicaltrials.gov/show/NCT00310180 18. Rutgers E, et al. The EORTC 10041/BIG 03–04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer. 2011 Dec; 47(18):2742–9. Epub 2011 Nov 1. 19. Paik S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006 Aug; 24(23): 3726–34. Epub 2006 May 23. 20. Albain KS, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010 Jan;11(1):55– 65. Epub 2009 Dec 10. 21. Small G. W, et al Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res. 2007 May;67(9):4459– 66. 22. de Azambuja E, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007 May;96(10):1504-13. Epub 2007 Apr 24. 23. Ellis MJ, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 2003 Oct;63(19):6523-31. 24. Dowsett M, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007 Jan;99(2):167-70. 25. Hu Z, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006 Apr;7:96. 26. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011 Aug;378(9793):771-84. Epub 2011 Jul 28. 27. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013 Mar;381(9869):805–16. 28. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00003678, Tamoxifen in Treating Women With Breast Cancer (The aTTom Trial); 1999 Nov [Last updated 2007 Mar]; Available from: http://clinicaltrials.gov/show/ NCT00310180

94